Menu
Search
|

Menu

Close
X

CymaBay Therapeutics Inc CBAY.OQ (NASDAQ Stock Exchange Capital Market)

14.98 USD
+0.11 (+0.74%)
As of Feb 17
chart
Previous Close 14.87
Open 14.85
Volume 315,368
3m Avg Volume 217,589
Today’s High 15.25
Today’s Low 14.56
52 Week High 15.25
52 Week Low 2.59
Shares Outstanding (mil) 43.76
Market Capitalization (mil) 358.81
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
5
FY16
0
FY15
0
EPS (USD)
FY17
-0.717
FY16
-1.137
FY15
-0.768
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
74.86
5.77
Price to Book (MRQ)
vs sector
110.22
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
350.44
16.52
LT Debt to Equity (MRQ)
vs sector
215.01
12.22
Return on Investment (TTM)
vs sector
-182.71
14.43
Return on Equity (TTM)
vs sector
-308.78
16.13

EXECUTIVE LEADERSHIP

Robert Wills
Chairman of the Board, Since 2015
Salary: --
Bonus: --
Sujal Shah
President, Chief Executive Officer, Since 2017
Salary: $330,000.00
Bonus: $150,000.00
Charles McWherter
Senior Vice President, Chief Scientific Officer, Since
Salary: --
Bonus: --
Daniel Menold
Vice President - Finance, Principal Financial Officer, Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Kirk Rosemark
Vice President - Regulatory Affairs and Quality Assurance, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

7999 Gateway Blvd Ste 130
NEWARK   CA   94560-1188

Phone: +1510.2938800

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

SPONSORED STORIES